PD12 Cost Effectiveness Analysis of Nivolumab Plus Ipilimumab for First-Line Treatment of Advanced Non-Small Cell Lung Cancer in China
International Journal of Technology Assessment in Health Care（2024）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要